
Miriam E. Tucker
Contributing Writer at Medscape
Contributing Writer at The Washington Post
Contributing Writer at Freelance
Writer/journalist specializing in medicine/health. Living with type 1 diabetes since 1973.
Articles
-
3 weeks ago |
medscape.com | Miriam E. Tucker
A new consensus report from the American Diabetes Association (ADA) provides a practice-oriented framework for screening and managing metabolic dysfunction–associated steatotic liver disease (MASLD) in people with diabetes and prediabetes. Published online on May 28, 2025, in Diabetes Care, the report is a comprehensive update to the recommendations the ADA released in 2023.
-
1 month ago |
portugues.medscape.com | Miriam E. Tucker
Dados inéditos sobre os benefícios dos novos medicamentos antiobesidade para algumas doenças cutâneas crônicas sugerem um potencial uso na dermatologia, bem como um papel ativo para dermatologistas no controle da obesidade. Os agonistas do receptor do peptídeo 1 glucagonoide (GLP-1) foram desenvolvidos inicialmente para o tratamento do diabetes mellitus do tipo 2 (DM2), mas logo despontaram como medicamentos antiobesidade, usados com o objetivo de promover a perda de peso.
-
1 month ago |
medscape.com | Miriam E. Tucker
ORLANDO, Fla. — A program at Duke University School of Nursing, Durham, North Carolina, is currently one of just two in the United States that trains nurse practitioners (NPs) to provide endocrine specialty care, but more could be on the way.
-
1 month ago |
medscape.com | Miriam E. Tucker
ORLANDO, Florida — Extreme fatigue, bone loss, and abdominal pain are real-world adverse events noted with the use of glucagon-like peptide 1 receptor agonists (GLP-1s) that may not have been apparent from the clinical trials. In a wide-ranging “meet the professor” lecture at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, obesity expert W. Timothy Garvey, MD, the Charles E.
-
1 month ago |
medscape.com | Miriam E. Tucker
ORLANDO, Fla. — After 2 years of treatment with the parathyroid hormone (PTH) analog palopegteriparatide (Yorvipath), adults with chronic hypoparathyroidism demonstrated continued improvement in renal function and skeletal dynamics, with no new safety issues identified. In hypoparathyroidism, low levels of PTH lead to hypocalcemia, hypercalciuria, and kidney damage, as well as reduced bone turnover and elevated fracture risk.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 10K
- Tweets
- 31K
- DMs Open
- Yes

RT @mariashriver: In a historic and unprecedented move, all of the institutions at the @NIH have signed on to and sent a letter, the Bethes…

RT @AmerMedicalAssn: Today’s action to remove the 17 sitting members of ACIP undermines trust and upends a transparent process that has sav…

RT @JeromeAdamsMD: As a physician and former U.S. Surgeon General, I am deeply concerned by the unprecedented decision to remove all 17 mem…